Detalles de la búsqueda
1.
A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT.
Respiration
; 98(1): 19-28, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30965332
2.
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
J Hepatol
; 62(2): 294-302, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25239078
3.
Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics.
Pharmaceutics
; 16(4)2024 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38675225
4.
Impact of P-gp inhibition on systemic exposure of pralsetinib and dosing considerations.
Clin Transl Sci
; 17(6): e13818, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38807449
5.
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Thyroid
; 34(1): 26-40, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38009200
6.
Hepatocellular adenoma in glycogen storage disorder type I: a clinicopathological and molecular study.
Histopathology
; 60(6B): E58-65, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22372484
7.
Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial.
Inflamm Bowel Dis
; 28(9): 1348-1356, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34849918
8.
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
Lancet Gastroenterol Hepatol
; 7(1): 17-27, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34798036
9.
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Lancet Gastroenterol Hepatol
; 7(2): 128-140, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34798039
10.
Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells.
Hepatology
; 50(1): 130-42, 2009 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-19437492
11.
Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial.
Inflamm Bowel Dis
; 28(10): e143, 2022 Oct 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35366308
12.
Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
PLoS One
; 11(1): e0145409, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26752189
13.
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.
Hepatol Int
; 10(3): 478-87, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26886127
14.
Contrasting Pattern of Chronic Inflammatory Bowel Disease in Primary and Autoimmune Sclerosing Cholangitis.
EBioMedicine
; 2(10): 1523-7, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26629548
15.
Risk factors for focal nodular hyperplasia of the liver: an Italian case-control study.
Am J Gastroenterol
; 97(9): 2371-3, 2002 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-12358258
16.
Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case-control study.
Am J Obstet Gynecol
; 186(2): 195-7, 2002 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-11854634
Resultados
1 -
16
de 16
1
Próxima >
>>